NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Stoke Therapeutics, Inc. STOK
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$184.4M
▲ 404.5% vs FY2024
EPS · FY25
$-0.12
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-2.4%
Net margin · FY25
-3.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 184.4M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 4 cents on every revenue dollar this year.
Per share
USD -0.12
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-2.4%
Return on equity, FY2025
ROE
Operating margin-11.2%
Net margin-3.7%
Return on assets-2.0%
Each USD of equity lost 2 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+145.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+61.1%
Change, 10 years—
The share count grew 61% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 418.4M
total assets, end of FY2025
Total assetsUSD 418.4M
EquityUSD 352.5M
CashUSD 84.2M
Current ratio5.28×
Equity funds 84% of total assets.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.2
0.0
0.0
0.0
·
·
·
·
Operating income $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
Income tax $B
0.0
·
·
·
·
·
·
·
Net income $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−0.12
−1.65
−2.38
−2.60
−2.34
−1.56
−1.80
−17.65
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−2.4
−45.8
−60.8
−50.2
−34.1
−20.5
−19.6
−24.1
Shares out B
0.06
0.05
0.05
0.04
0.04
0.04
0.03
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
24 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed